What Is Crystalline Silica? Forms, Health Risks and Where It Is Used

Published: Source: Silica Raw Materials News Section: Silica Raw Materials

📌 Key Takeaways

  • Topic: Silica COA: What a Certificate of Analysis Should Include and How to Verify It
  • Keywords: microsilica for cement
  • Published: 2026-11-20 01:47:25
  • Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals

Colloidal Silica Supplier: How to Choose by Particle Size, Stability and pH

Quartz Sand Price: 2026 Price Ranges by Purity and Mesh Size
What Is Hydrophilic Fumed Silica? Properties, BET Grades and Typical Uses
MSNs are SiO 2 nanoparticles [ 2 ] with a pore diameter between 2 and 50 nm [ 3, 4 ] and with a total diameter of a maximum of 1 µm. Their use in drug delivery dates to the early 1990s when they were synthesized for various scientific applications [ 5 ]. The material known as mesoporous silica was discovered by Mobil Oil Corporation in 1992 [ 6 ]. Their first drug delivery application was demonstrated in 2001 when MCM-41 silica was used to release ibuprofen [ 7 ]. Since then, MSNs have become an increasingly popular drug delivery system due to their advantageous properties and have been typically recognized as secure (GRAS) by the FDA. Tiny SNPs have been approved for human clinical imaging studies, setting the stage for their use in clinical applications of drug delivery. The number of related research activities is continuously increasing each year, expanding their role in cancer treatment, gene delivery, and oral illness therapy [ 5 ]. Their pore size is located between microporous and macroporous systems. They can be used in diverse shapes (sphere, cube, ellipsoid, rod) and sizes, with different pore sizes and pore structures [ 2, 3, 4, 8, 9, 10 ]. They have a high degree of stability [ 8 ] and a rigid framework, which results in resistance to temperature, pH, enzymatic degradation, and mechanical force [ 4 ]. Thanks to the large number of pores, they have a massive particular surface region (approx. 700-1300 m 2 /g) and pore volume (approx. 0.5-1.5 cm 3 /g), which enables effective adsorption of diverse molecules [ 2, 3, 4, 8, 9, 10 ]. By changing the pore size distribution, the range of adsorbable molecules can be controlled [ 3 ], which also lets separation based on size exclusion, which means selective adsorption of molecules of certain sizes. Depending on the size of the pores, tiny molecules together with high molecular weight proteins can be transported into the pores [ 8 ]. In addition, chemical separation is also possible if the surface of the pores is coated with specific functional groups [ 4 ], which enables the separation of the APIs according to their structure [ 4 ]. Such modifications may include the setting of hydrophilicity/hydrophobicity of the surface, depending on whether the adsorption of hydrophobic or hydrophilic molecules is targeted [ 4 ]. By inserting different functional groups, the surface charge can also be controlled so that certain molecules will bind more efficiently. MSNs have a negative surface charge in biological environments, which promotes the electrostatic adsorption of positively charged APIs in the pores [ 10 ]. Moreover, the biological markers attached to the surface of the nanoparticles enable the drug-carrying system to deliver the API in a tissue-specific manner [ 2, 4, 8, 9, 10 ]. A substantial problem is the premature release of the API from the pores during transport [ 4, 8 ], which can be solved by utilizing gatekeepers that respond to special stimuli and keep the pores closed until the stimulus [ 2, 4, 8 ]. In this way, controlled drug delivery and stimuli-responsive release can be achieved [ 2, 4, 9 ]. The drug release could be triggered by temperature, pH, redox potential, light, enzymes, magnetic field, or different ligands [ 4, 8, 11 ].
Silica Powder Supplier Guide: How to Compare Grades, Quality and Pricing
In the case of solvent-free processes, the main advantage is that it is not necessary to get rid of the solvent residue from the system at the conclusion of the process, and the concentration of the API can also be controlled [ 36, 37 ]. Techniques employed in this class comprise physical mixing, co-milling, and melt sorption methods. The simplest approach is physical mixing [ 37 ], where fast drug filling is possible without special equipment. During direct mixing of the mesoporous carrier and the drug, the silanol groups on the surface of the silica bind the drug molecules. Nonetheless, its application is limited because it can be used largely for water-soluble molecules [ 37, 56 ]. Another method is co-milling, during which the mixture of the API and the nanocarrier is milled together [ 36, 37, 56 ]. In the case of the melt sorption method, the mixture of the API and the carrier system is heated above the melting point of the API under continuous stirring, while the melt is absorbed into the pores [ 36, 37 ]. After that, the system is cooled under lowered pressure, so that the molecules will be in an amorphous state in the pores [ 36, 37 ]. Nevertheless, this technique cannot be used in the case of heat-sensitive materials, due to the considerable thermal decomposition [ 20 ]. Microwave radiation can also be used for melting [ 2, 36 ].
Imerys Silica: Product Range, Minerals and Applications

Silica Gel Manufacturer: Product Types, Quality Standards and Selection Guide

What is silica (SiO₂)?

silica for beer clarification Even though MSNs can usually be recognized as secure products, their use during therapy may cause side impacts in the body [ 1, 2, 29 ]. Due to their small size and large surface area, they may tend to accumulate in the body, or certain organs (liver, spleen, kidney, lung) and may even be toxic in higher concentrations, which is a clear disadvantage [ 1, 4, 27 ]. The silanol groups (Si-OH) on their surface can interact with the phospholipid layer of the cell membrane, thereby causing cell lysis or, in extreme cases, hemolysis [ 4, 8 ]. In severe cases, the lack of hemocompatibility can also cause issues [ 2 ]. Overall, indications of cytotoxicity, haemotoxicity, and genotoxicity were also found [ 4, 8 ]. That is why the biocompatibility of all comparable preparations must be strictly controlled [ 2, 4, 27 ]. The physicochemical features (particle size, particle morphology, surface chemistry, pore structure, etc.) of nanocarriers also have a major impact on toxicity [ 2, 4, 8, 30 ]. Additionally, further attention must be paid to the biological influences of their decomposition products, because they may also cause unwanted side influences [ 1 ]. The breakdown of silica nanoparticles in the body can take up to a few days. The opening hydration is followed by hydrolysis, and, in the end, they are excreted in the urine in the form of silicic acid [ 1 ]. Nevertheless, the literature is contradictory in this regard [ 31 ]. Some experiments show no considerable cytotoxic effect [ 18, 31 ], while other experiments say otherwise [ 23, 32 ]. For example, an in vitro study was performed with multiple concentrations, surfaces, and particle sizes (60 nm, 100 nm, 300 nm) of MSNs, with an exposure time of 72 h [ 18 ]. This study shown no significant cytotoxic influence in any of the cell lines tested (human cervical (HeLA), epithelial lung (A549), and glioblastoma (U251)) [ 18 ]. Ismail et al. investigated the cytotoxic effect of silica nanoparticles in vivo in mouse models [ 33 ]. Amorphous silica nanoparticles were administered to the animals orally, at a dose of 150 mg/kg/day, for 3 months. Based on these mouse models, no toxic effects were detected under sub-chronic treatment of the nanoparticles [ 31 ]. In another study, particle size (15 nm, 60 nm, 200 nm) dependent impact was observed on cellular viability in all four cell lines tested (THP-1 derived macrophages, A549 epithelial cells, HaCaT keratinocytes, and NRK-52E kidney cells) [ 23 ]. Smaller particles caused notable toxicity on each cell line, after the exposure time of 24 h, in contrast to the larger particles, which demonstrated no cytotoxic impact [ 23 ]. A comparable outcome has been published to verify the toxic characteristic of mesoporous silica. In this in vitro study, the researchers investigated the effect of MSNs with an average size of 7 nm on cell viability at three different concentrations. After 72 h of exposure, only the highest concentration (62.5 µg/mL) caused a substantial decrease in cell viability of human lung fibroblast cells. This toxicity occurred in a time- and dose-dependent manner [ 32 ]. In an in vivo mouse model, MacCuaig et al. presented coating-dependent impacts after repeated intravenous administration of MSNs. Chitosan-coated MSNs induced minor organ changes and were the most biocompatible. Uncoated and especially PEG-coated MSNs (especially 2K PEG) moderately augmented pre-existing vascular or organ lesions, implying that PEGylation has the potential to augment chronic risks, while chitosan enables safer long-term use [ 34 ]. An in vitro study of Barguilla et al. exposed epithelial lung cells to bare, PEG-functionalized, or galacto-oligosaccharide-functionalized MSNs for eight weeks. There was no reported long-term DNA damage, but malignant-like alterations like anchorage-independent growth, boosted migration/invasion, and secretome-facilitated tumor promotion were triggered by PEG- and GAL-functionalized MSNs. Naked MSNs did not cause such alterations and were determined to be safer [ 35 ]. Coating, on the whole, exerts a significant impact on the safety of MSNs. Uncoated MSNs are relatively innocuous; the most biocompatible coatings were achieved with chitosan, but PEG and carbohydrate functionalization can be dangerous in the long run, from vascular toxicity in vivo to tumor-promoting activity in vitro [ 34, 35 ].

What is the difference between fumed silica and precipitated silica?

silica surface area 2.4. Surface Chemistry

What drives silica raw material prices?

ultra pure silica 92. Paul S., Guo Y., Wang C., Dun J., Calvin Sun C. Enabling direct compression tablet formulation of celecoxib by simultaneously removing punch sticking, boosting manufacturability, and improving dissolution through co-processing with a mesoporous carrier. Int. J. Pharm. 2023;641:123041. doi: 10.1016/j.ijpharm.2023.123041. [ DOI ] [ PubMed ] [ Google Scholar ]

Cite this article: Silica Raw Materials News. "Silica 99.99% (4N): Specifications, Impurity Limits and Applications ." Published 2026-11-20 01:47:25. /news/article.html
Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.